| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 152, Issue 1 117-128, Copyright © 1994 by American Association of Immunologists
ARTICLES |
JJ Westendorf, GJ Ahmann, RJ Armitage, MK Spriggs, JA Lust, PR Greipp, JA Katzmann and DF Jelinek
Department of Immunology, Mayo Clinic, Rochester, MN 55905.
Myeloma is a neoplasia characterized by the accumulation of malignant plasma cells in the bone marrow. In these studies, we have demonstrated that CD40 is expressed in human myeloma cells and have used a recently established IL-6-dependent myeloma cell line, ANBL-6, to examine the potential function of CD40 expression in myeloma cells. In addition to its expression on the ANBL-6 cells, we show that CD40 is expressed on freshly isolated myeloma cells from seven of seven patients tested. To address the role of CD40 expression in myeloma cells, we have examined the responsiveness of the ANBL-6 cell line to a CD40-specific mAb, G28- 5. This cell line has previously been shown to proliferate only in response to IL-6. Of interest in this study, G28-5 also induced proliferation of the ANBL-6 cells. This proliferation was substantially inhibited by an IL-6-neutralizing mAb. Analysis of ANBL-6 cell culture supernatants by ELISA demonstrated that G28-5-stimulated cells secreted significant levels of IL-6, whereas unstimulated cell culture supernatants contained undetectable levels of IL-6. Furthermore, CV- 1/EBNA cells expressing the human CD40 ligand also induced the proliferation of the ANBL-6 cell line, an effect that was inhibited by the anti-IL-6 mAb. Lastly, RNA blot analysis demonstrated an increase in IL-6 message in G28-5-stimulated ANBL-6 cells over unstimulated cells. These results indicate that the primary mechanism of anti-CD40- stimulated proliferation of the ANBL-6 cells is the induction of autocrine IL-6 production. Moreover, these data suggest that the expression of CD40 in malignant plasma cells may play a role in tumor cell expansion, possibly by stimulating the induction of autocrine IL-6 secretion.
This article has been cited by other articles:
|
|
 |
|
  T. Khong, J. Sharkey, and A. Spencer The effect of azacitidine on interleukin-6 signaling and nuclear factor-{kappa}B activation and its in vitro and in vivo activity against multiple myeloma Haematologica, June 1, 2008; 93(6): 860 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Law, K. A. Gordon, J. Collier, K. Klussman, J. A. McEarchern, C. G. Cerveny, B. J. Mixan, W. P. Lee, Z. Lin, P. Valdez, et al. Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40 Cancer Res., September 15, 2005; 65(18): 8331 - 8338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Tai, X. Li, X. Tong, D. Santos, T. Otsuki, L. Catley, O. Tournilhac, K. Podar, T. Hideshima, R. Schlossman, et al. Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma Cancer Res., July 1, 2005; 65(13): 5898 - 5906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Abroun, H. Ishikawa, N. Tsuyama, S. Liu, F.-J. Li, K.-i. Otsuyama, X. Zheng, M. Obata, and M. M. Kawano Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor {alpha} Blood, March 15, 2004; 103(6): 2291 - 2298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Tai, K. Podar, N. Mitsiades, B. Lin, C. Mitsiades, D. Gupta, M. Akiyama, L. Catley, T. Hideshima, N. C. Munshi, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling Blood, April 1, 2003; 101(7): 2762 - 2769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Tai, K. Podar, D. Gupta, B. Lin, G. Young, M. Akiyama, and K. C. Anderson CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells Blood, February 15, 2002; 99(4): 1419 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Depraetere, L. Verhoye, G. Leclercq, and G. Leroux-Roels Human B Cell Growth and Differentiation in the Spleen of Immunodeficient Mice J. Immunol., March 1, 2001; 166(5): 2929 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Teoh, Y.-T. Tai, M. Urashima, S. Shirahama, M. Matsuzaki, D. Chauhan, S. P. Treon, N. Raje, T. Hideshima, Y. Shima, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines Blood, February 1, 2000; 95(3): 1039 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tarte, X.-G. Zhang, E. Legouffe, C. Hertog, M. Mehtali, J.-F. Rossi, and B. Klein Induced Expression of B7-1 on Myeloma Cells Following Retroviral Gene Transfer Results in Tumor-Specific Recognition by Cytotoxic T Cells J. Immunol., July 1, 1999; 163(1): 514 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, A. Bharti, N. Raje, E. Gustafson, G. S. Pinkus, J. L. Pinkus, G. Teoh, T. Hideshima, S. P. Treon, J. D. Fingeroth, et al. Detection of Kaposi's Sarcoma Herpesvirus DNA Sequences in Multiple Myeloma Bone Marrow Stromal Cells Blood, March 1, 1999; 93(5): 1482 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Dallas, I. R. Garrett, B. O. Oyajobi, M. R. Dallas, B. F. Boyce, F. Bauss, J. Radl, and G. R. Mundy Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease Blood, March 1, 1999; 93(5): 1697 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-h. Xu, S. Sharma, A. Gardner, Y. Tu, A. Raitano, C. Sawyers, and A. Lichtenstein Interleukin-6-Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway Blood, July 1, 1998; 92(1): 241 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yi, S. Dabadghao, A. Osterborg, S. Bergenbrant, and G. Holm Myeloma Bone Marrow Plasma Cells: Evidence for Their Capacity as Antigen-Presenting Cells Blood, September 1, 1997; 90(5): 1960 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Urashima, G. Teoh, D. Chauhan, Y. Hoshi, A. Ogata, S. P. Treon, R. L. Schlossman, and K. C. Anderson Interleukin-6 Overcomes p21WAF1 Upregulation and G1 Growth Arrest Induced by Dexamethasone and Interferon-gamma in Multiple Myeloma Cells Blood, July 1, 1997; 90(1): 279 - 289. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
